885 related articles for article (PubMed ID: 18465450)
1. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
3. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
4. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
5. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
[TBL] [Abstract][Full Text] [Related]
6. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
[TBL] [Abstract][Full Text] [Related]
7. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
8. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
Daoussis D; Liossis SN; Solomou EE; Tsanaktsi A; Bounia K; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Arthritis Rheum; 2010 Jan; 62(1):150-8. PubMed ID: 20039407
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.
Schotte H; Schlüter B; Willeke P; Mickholz E; Schorat MA; Domschke W; Gaubitz M
Rheumatology (Oxford); 2004 Aug; 43(8):960-4. PubMed ID: 15026584
[TBL] [Abstract][Full Text] [Related]
10. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease.
Chen DY; Hsieh TY; Chen YM; Hsieh CW; Lan JL; Lin FJ
Gerontology; 2009; 55(3):250-8. PubMed ID: 18849599
[TBL] [Abstract][Full Text] [Related]
11. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
Yazdani-Biuki B; Stadlmaier E; Mulabecirovic A; Brezinschek R; Tilz G; Demel U; Mueller T; Brickmann K; Graninger WB; Brezinschek HP
Ann Rheum Dis; 2005 Aug; 64(8):1224-6. PubMed ID: 16014683
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
14. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
[TBL] [Abstract][Full Text] [Related]
15. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
16. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.
Jamnitski A; Visman IM; Peters MJ; Dijkmans BA; Voskuyl AE; Nurmohamed MT
Ann Rheum Dis; 2010 Nov; 69(11):1929-33. PubMed ID: 20498216
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
Choi ST; Kim JH; Kang EJ; Lee SW; Park MC; Park YB; Lee SK
Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
[TBL] [Abstract][Full Text] [Related]
19. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]